The Swedish Financial Supervisory Authority initiates investigation of Klaria Pharma’s handling and disclosing of inside information
The Swedish Financial Supervisory Authority (“SFSA”) has today notified Klaria Pharma Holding AB (“Klaria” or the “Company”) that the SFSA has decided to initiate an investigation of whether the Company has fulfilled its obligations pursuant to Article 17 and Article 18 of the EU Market Abuse Regulation (“MAR”) in connection with the rights issue of shares in the Company that ended on December 21, 2022. According to the notification received by the Company today it is further stated that the SFSA investigates if the authority should intervene against the Company in accordance with Chapter 2, Section 2, items 2, 3 and 4 of the law (2016:1306) with supplementary provisions to MAR (Sw. lag (2016:1306) med kompletterande bestämmelser till EU:s marknadsmissbruksförordning). The Company will in accordance with the SFSA’s notification provide the SFSA a statement at the latest on April 20, 2023.
For more information, please contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
Tel: +46 (0) 8-446 42 99
This information is information that Klaria Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on March 27, 2023 8:15 pm CEST.
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria Pharma is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor ([email protected], +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.
